assessments were used to calculate the mean ISI for each candidate. The mean ISI for RBT/16 was 1.21 (betweenlaboratory coefficient of variation [CV]: 4.6%), and the mean ISI for rTF/16 was 1.11 (between-laboratory CV: 5.7-%). Conclusions: The between-laboratory variation of the ISI for candidate material RBT/16 was similar to that of the Fourth International Standard (RBT/05), and the between-laboratory variation of the ISI for candidate material rTF/16 was slightly higher than that of the Fourth International Standard (rTF/09). The candidate materials have been accepted by WHO as the Fifth International Standards for thromboplastin, rabbit plain, and thromboplastin, recombinant, human, plain.
Essentials
• Two candidate International Standards for thromboplastin (coded RBT/16 and rTF/16) are proposed.
• International Sensitivity Index (ISI) of proposed standards was assessed in a 20-centre study.
• The mean ISI for RBT/16 was 1.21 with a between-centre coefficient of variation of 4.6%.
• The mean ISI for rTF/16 was 1.11 with a between-centre coefficient of variation of 5.7%.
Summary. Background:
The availability of International Standards for thromboplastin is essential for the calibration of routine reagents and hence the calculation of the International Normalized Ratio (INR). Stocks of the current Fourth International Standards are running low. Candidate replacement materials have been prepared. This article describes the calibration of the proposed Fifth International Standards for thromboplastin, rabbit, plain (coded RBT/16) and for thromboplastin, recombinant, human, plain (coded rTF/16). Methods: An international collaborative study was carried out for the assignment of International Sensitivity Indexes (ISIs) to the candidate materials, according to the World Health Organization (WHO) guidelines for thromboplastins and plasma used to control oral anticoagulant therapy with vitamin K antagonists. Results: Results were obtained from 20 laboratories. In several cases, deviations from the ISI calibration model were observed, but the average INR deviation attributabled to the model was not greater than 10%. Only valid ISI
Introduction
Treatment with vitamin K antagonists (VKAs) must be monitored to adjust the dose if necessary. The primary laboratory method for monitoring of VKA treatment is the prothrombin time (PT) test. The PT test is performed with a thromboplastin reagent and a method or instrument to determine the coagulation time in seconds. Various types of thromboplastin are prepared commercially, and, in order to be able to interpret the results of the PT test, it is essential for each reagent to be correctly calibrated [1] . This will ensure that the results of tests with different products and batches can be compared. A procedure for the calibration of thromboplastins using a logarithmic plot of PTs has been developed. With this procedure, the definition of a calibration parameter called the International Sensitivity Index (ISI) became feasible. It is possible to express PT results on a common scale, i.e. the International Normalized Ratio (INR), if the ISI of the thromboplastin used is known.
Two International Standards for thromboplastin were available until 2016 for the calibration of secondary standards or commercial thromboplastin preparations: the Fourth International Standard for thromboplastin, rabbit, plain (coded RBT/05), and the Fourth International Standard for thromboplastin, human, recombinant (coded rTF/09) [2, 3] . In general, the calibration of a given thromboplastin reagent is more precise if performed against an International Standard of similar composition and from the same species [4, 5] . Thus, plain rabbit thromboplastins should be calibrated against the Fourth International Standard for thromboplastin, rabbit, plain, and plain human thromboplastins should be calibrated against the Fourth International Standard for thromboplastin, human, recombinant.
Stocks of both rTF/09 and RBT/05 were running low, and replacements were required. Candidate replacement materials have been prepared for thromboplastin, human, recombinant, plain (provisionally coded 14/001, eventually coded rTF/16) and for thromboplastin, rabbit, plain (provisionally coded 15/001, eventually coded RBT/16). The calibration of the candidate replacement materials was to be carried out as part of an international multicenter collaborative study using fresh plasma samples from VKA-treated patients and healthy individuals, and manual techniques for PT determination. The ISI assigned to each replacement material should be the mean of the ISIs obtained by calibration with all existing World Health Organization (WHO) International Standards [6] . The present report deals with the results of an international collaborative study organized under the auspices of the Scientific and Standardization Committee (SSC) of the ISTH for the calibration of the two candidate replacement materials. A set of four lyophilized plasma samples representing different levels of anticoagulation was included in the study for assessment of the betweenlaboratory variation of the INR.
Materials and methods

Candidate materials for thromboplastin International Standards
Details of the candidate materials for thromboplastin International Standards are given in Table 1 . Following reconstitution of each ampoule of thromboplastin and pooling, the working reagent was kept at room temperature and used within 2 h of reconstitution. Actual testing was performed as follows. Glass test tubes were placed in a water bath for 5 min to reach 37°C; 0.2 mL of the working reagent (either RBT/16 or rTF/16) was pipetted into the test tube and incubated for 2 min to reach 37°C; and 0.1 mL of non-prewarmed test plasma was then pipetted into the test tube, and a stopwatch was started immediately. The test tube was shaken to mix the content and the test tube was regularly tilted back and forth until the clot formed. The clotting time was recorded in seconds and 1/10 s.
Control plasma samples
A set of four lyophilized control plasma samples was provided by Technoclone (Vienna, Austria). Sample A was obtained from healthy donors. Samples B, C and D were prepared from donors who had been receiving long-term therapy with VKAs. Each vial of control plasma was reconstituted with 1.0 mL of water. Following reconstitution, the sample was kept at room temperature and used within 2 h of reconstitution.
Design of the collaborative study for ISI value assignment Twenty laboratories from Europe, North America, South America, Asia and Australia were invited to participate in the collaborative study. Fourteen of these had participated in the previous collaborative study for the calibration of rTF/09 (3). The candidate materials (14/001 and 15/001) and the current International Standards (rTF/09 and RBT/05) were tested in each laboratory by the same operator with the manual (tilt tube) technique, according to a study protocol with detailed instructions. Each laboratory was permitted to draw blood specimens with its routine blood collection system. Test plasmas were freshly prepared from healthy ('normal') subjects and patients receiving long-term therapy with VKAs. Participants were instructed to select patient plasmas with PTs corresponding to an INR interval from 1.5 to 4.5. In addition to the fresh plasmas, four lyophilized control plasmas were included. To account for the effect of interday variation, PT measurements were performed in each laboratory on 10 different days. Participants were instructed to include, on each, day plasmas from two healthy individuals and six patients treated with VKAs. Healthy individuals and patients had to be different on each working day. To minimize the effect of preanalytic plasma instability on the relationship between thromboplastins, the order of testing was changed each day. The order of testing was specified in the data collection form. The collaborative study was carried out from October 2015 until February 2016.
Statistical methods
Calculation of the mean normal PT Each laboratory determined PTs in fresh plasmas of 20 healthy ISI validity assessment Each and every ISI assessment was checked for validity. The within-laboratory coefficient of variation (CV) of the slope b of the orthogonal regression line for normal samples + patient samples should be 3% or less [1] . ISI assessments with a within-laboratory CV b of the slope b larger than 3% were rejected. Second, the adequacy of the ISI model was checked. Although there is good evidence that the calibration relationship defined in a double-logarithmic plot of PTs is usually linear, and that the same line represents data points for both patients and healthy subjects, the possibility of departure from these assumptions cannot be ruled out. To assess the magnitude of INR deviations, an orthogonal regression line was calculated for patients' samples only (i.e. without normal samples): 
where d is a scale parameter, R is the PT ratio, and ISI Ref is the ISI of the Reference Standard. The scale parameter d can be estimated as 
Results
Results were obtained from 20 laboratories. Becton Dickinson (Plymouth, UK) Vacutainer blood collection systems were used by 10 laboratories, Greiner (Kremsm€ unster, Austria) Bio One Vacuette tubes were used by seven, and Sarstedt (N€ umbrecht, Germany) Monovette tubes were used by three. Sodium citrate concentrations in the blood collection systems varied between 0.105 mol L À1 and 0.109 mol L À1 according to the respective manufacturers. Preliminary orthogonal regression lines were calculated for each laboratory and for all PT results provided (step 1). Each of the new thromboplastin preparations could be calibrated separately against rTF/09 and against RBT/05. The average within-laboratory variation of the orthogonal regression slope b was greater for cross-species calibrations than for like-to-like calibrations ( Table 2 ). The preliminary ISI was calculated from the preliminary orthogonal regression lines. The between-laboratory variation of the preliminary ISI was greater for cross-species calibrations than for like-to-like calibrations (Table 2) . In some laboratories, outliers and samples with INRs of < 1.5 or > 4.5 were detected (Table 3) . After exclusion of these samples, orthogonal regression lines and ISIs were recalculated. Exclusion of outliers and samples with INR of < 1.5 or > 4.5 had only minor effects on the average ISI and the variation of the ISI (Table 3) . There were three ISI determinations for which CV b was > 3% (Table 3) . These three ISI determinations were rejected.
Validity of the ISI
Orthogonal regression lines (Y = a 0 + b 0 X) were calculated for the natural logarithms of patients' PTs only. The average values for the intercept (a 0 ) and slope (b 0 ) are shown in Table 4 . The orthogonal regression lines were used to assess the validity of each ISI determination. We assessed the difference between the INR calculated with the ISI and the INR calculated with the line Y = a 0 + b 0 X. If the INR difference was > 10% at the limits of the therapeutic range (i.e. at INR = 2.0 and at INR = 4.5), the ISI was deemed to be non-valid. In a number of cases, non-validity of the ISI was observed (Table 4) . In like-to-like calibrations, i.e. when rTF/16 was calibrated against rTF/09 and when RBT/16 was calibrated against RBT/05, the numbers of non-valid calibrations were zero and one out of 20 calibrations, respectively. In unlike calibrations, i.e. when rTF/16 was calibrated against RBT/05 and when RBT/16 was calibrated against rTF/09, the numbers of non-valid calibra- For calculation of the final average ISI for each of the new thromboplastin standards, the calibrations with CV b > 3% and non-valid calibrations were excluded ( Table 5 ). The overall mean ISI and between-laboratory CV of the ISI for the new International Standard rTF/16 were 1.11% and 5.7%, respectively. The overall mean ISI and between-laboratory CV of the ISI for the new International Standard RBT/16 were 1.21% and 4.6%, respectively.
INRs were calculated for the four lyophilized control plasma samples by use of the PTs determined with the four thromboplastins ( determined with the new International Standards, not only by use of the average ISI values given in Table 5 
Discussion
The purpose of the present study was to assign ISI values to two new International Standards for thromboplastins, one prepared from recombinant human tissue factor and the other from rabbit brain. ISI assignment was performed by calibration against all existing WHO International Standards in an international multicenter study, to ensure consistency of results between different routes of calibration [6] . Within-laboratory and between-laboratory variation of the ISI was similar to the variation observed in previous multicenter studies. As in previous studies, variation was greater when unlike thromboplastin reagents (i.e. recombinant human versus rabbit brain) were calibrated against each other than when like-to-like calibrations were performed. In an attempt to improve the quality of the average ISI, we excluded samples that were far away from the preliminary regression line (i.e. outliers) and samples with INRs beyond the therapeutic range (INR < 1.5 and INR > 4.5). The exclusion of these samples had little effect on the average ISI or the between-laboratory variation of the ISI (cf . Tables 2  and 3 ). The ISI model is based on the assumption that the mean logarithms of the PTs of normal samples lie on the orthogonal regression line through patients' samples [7] . The ISI model was valid for the calibration of rTF/16 against rTF/09 (Table 4 ). In a number of instances, there was a significant deviation from the assumption. Significant deviations were observed in the cross-species calibrations, i.e. human recombinant tissue factor versus rabbit brain thromboplastin (Table 4 ). The non-valid ISI assessments were excluded for the calculation of the overall mean ISI of the new International Standards (Table 5) . The overall between-laboratory variation of the ISI for rTF/16 (CV = 5.7%) was greater than that for RBT/16 (CV = 4.6%). The relatively high CV for rTF/16 is attributable to high variation of the calibration slopes for the What is the origin of the between-laboratory variation of the ISI? Exclusion of outlying samples and samples with INR < 1.5 or with INR > 4.5 had little effect on the between-laboratory variation (cf . Tables 2 and 3) . Previous studies have shown that differences in preanalytic conditions, such as different blood collection tubes and different sodium citrate concentrations, may influence the ISI [8] [9] [10] [11] [12] . Clotting times were different between the laboratories, not only for the fresh plasma samples but also for the lyophilized plasma samples (Fig. 1 ). There was a significant correlation between each laboratory's mean normal PT and each laboratory's mean PT for lyophilized normal plasma A. This observation suggests that there are systematic analytic differences between the laboratories. The possibility that clotting times determined with the manual technique depend on the operator cannot be excluded. It is not known whether the frequency of manual tilting of the test tube may influence the clotting time. Furthermore, it is not known whether the size and the composition of the glass test tube may influence the clotting time. Further work is needed to investigate these potential sources of bias between operators and equipment. Strict standardization of techniques and procedures may reduce between-laboratory variation in future calibration exercises.
Long-term stability of the ISI of the International Standards is an essential requirement, and has been demonstrated for rTF/09 and RBT/05 in a previous study [13] . Stability monitoring of the new International Standards should be started.
The results reported in this article were presented at the meeting of the subcommittee on control of anticoagulation of the SSC/ISTH, in Montpellier (France), May 2016. The proposed preparations were established as the Fifth International Standards for thromboplastin at the Table 5 . †See Table 4 . 
